Significance of BRAF mutations in papillary thyroid carcinoma:: prognostic and therapeutic implications

被引：23

作者：

Groussin, L ^{[1
]}

Fagin, JA ^{[1
]}

机构：

[1] Univ Cincinnati, Div Endocrinol & Metab, Coll Med, Cincinnati, OH 45267 USA

来源：

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM | 2006年 / 2卷 / 04期

关键词：

D O I：

10.1038/ncpendmet0161

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Molecular analysis has transformed our current understanding of the etiology of papillary thyroid carcinoma (PTC). Activating mutations of components of the mitogen-activated protein kinase signal transduction pathway, including the serine/threonine kinase B-RAF, are frequently detected. The prognostic significance of theseBRAFmutations and the therapeutic implications for managing PTC are discussed.

引用

页码：180 / 181

页数：2

共 10 条

[1] PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma [J].

Castro, P ;

Rebocho, AP ;

Soares, RJ ;

Magalhaes, J ;

Roque, L ;

Trovisco, V ;

de Castro, IV ;

Cardoso-de-Oliveira, M ;

Fonseca, E ;

Soares, P ;

Sobrinho-Simoes, M .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (01) :213-220

[2] Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer [J].

Ciampi, R ;

Knauf, JA ;

Kerler, R ;

Gandhi, M ;

Zhu, ZW ;

Nikiforova, MN ;

Rabes, HM ;

Fagin, JA ;

Nikiforov, YE .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (01) :94-101

[3] Molecular classification of papillary thyroid carcinoma:: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis [J].

Giordano, TJ ;

Kuick, R ;

Thomas, DG ;

Misek, DE ;

Vinco, M ;

Sanders, D ;

Zhu, ZW ;

Ciampi, R ;

Roh, M ;

Shedden, K ;

Gauger, P ;

Doherty, G ;

Thompson, NW ;

Hanash, S ;

Koenig, RJ ;

Nikiforov, YE .

ONCOGENE, 2005, 24 (44) :6646-6656

[4]

Kimura ET, 2003, CANCER RES, V63, P1454

[5] Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation [J].

Knauf, JA ;

Ma, XL ;

Smith, EP ;

Zhang, L ;

Mitsutake, N ;

Liao, XH ;

Refetoff, S ;

Nikiforov, YE ;

Fagin, JA .

CANCER RESEARCH, 2005, 65 (10) :4238-4245

[6] BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas [J].

Nikiforova, MN ;

Kimura, ET ;

Gandhi, M ;

Biddinger, PW ;

Knauf, JA ;

Basolo, F ;

Zhu, ZW ;

Giannini, R ;

Salvatore, G ;

Fusco, A ;

Santoro, M ;

Fagin, JA ;

Nikiforov, YE .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) :5399-5404

[7]

OUYANG B, IN PRESS CLIN CANC R

[8] High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes [J].

Vasko, V ;

Hu, SY ;

Wu, GJ ;

Xing, JC ;

Larin, A ;

Savchenko, V ;

Trink, B ;

Xing, MZ .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (09) :5265-5269

[9] BRAF mutation in thyroid cancer [J].

Xing, M .

[10] BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer [J].

Xing, MZ ;

Westra, WH ;

Tufano, RP ;

Cohen, Y ;

Rosenbaum, E ;

Rhoden, KJ ;

Carson, KA ;

Vasko, V ;

Larin, A ;

Tallini, G ;

Tolaney, S ;

Holt, EH ;

Hui, P ;

Umbricht, CB ;

Basaria, S ;

Ewertz, M ;

Tufaro, AP ;

Califano, JA ;

Ringel, MD ;

Zeiger, MA ;

Sidransky, D ;

Ladenson, PW .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (12) :6373-6379

← 1 →